Context: Mangifera indica (Anacardiaceae) stem bark contains a rich content of mangiferin and is used traditionally in Indian Ayurvedic system to treat diabetes. Purpose of the study: To investigate anti-diabetic and hypolipidemic effects of mangiferin in type 1 and type 2 diabetic rats models. Streptozotocin was used to induce type 1 and type 2 diabetic rats. Mangiferin (at a dose 10 and 20mg/kg) was administrated intra-peritoneally in type 1 and type 2 diabetic rats daily up to 30 days. Biochemical parameters notably fasting blood sugar, total cholesterol, triglycerides, low-density lipoprotein, very low-density lipoprotein and high-density lipoprotein were estimated. In addition, in vitro alpha amylase and alpha glucosidase inhibitory effects of mangiferin were performed and IC 50 values were determined. Results: Mangiferin exhibited significant (P<0.05) anti-diabetic as well as hypolipidemic effects by lowering FBS, TC, TG, LDL, and VLDL levels; but also with elevation of HDL level in type 2 diabetic model rats. In addition, mangiferin showed appreciable alpha amylase inhibitory effect (IC 50 value 74.35±1.9µg/ml) and alpha glucosidase inhibitory effect (IC 50 41.88±3.9µg/ml) when compared with standard drug acarbose (IC 50 83.33±1.2µg/ml). Conclusions: Mangiferin showed anti-diabetic as well as hypolipidemic potentials in type 2 diabetic model rats. Therefore, mangiferin possess beneficial effects in the management of type 2 diabetes with hyperlipidemia.
Introduction
Diabetes is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The total number of people with diabetes is projected to explode from 171 million in 2000 to 366 million in 2030 [1] . The majority of diabetes is divided into two broad etiopathogenic categories. In the first category, type 1 diabetes occurs due to absolute deficiency of insulin and 5-10% of people are affected by this type of diabetes. In the other, much more prevalent category, type 2 diabetes occurs mostly due to combination of doi:10.5138/ijaps.2010.0976.1055.01009 insulin resistance and an inadequate compensatory insulin secretory response [2] . Diabetes is usually associated with hypertension, poor metabolic control, smoking and obesity [3, 4] . Modern medicines like biguanides, sulphonylureas and thiozolidinediones are available for the treatment of diabetes. But they also have undesired effects associated with their uses [5] . Alternative medicines particularly herbal medicines are available for the treatment of diabetes. Common advantages of herbal medicines are effectiveness, safety, affordability and acceptability [6] . Medicinal plants and their products have been used in the Indian traditional system of medicine and have shown experimental or clinical anti-diabetic activity [7, 8] . Medicinal Plants are a rich source of natural products. Medicinal plants and their products have been widely used for treatment of diabetic populace all around the world with less known scientific basis of their functioning [9, 10] . Hence, natural products from medicinal plants need to be investigated by scientific methods for their anti-diabetic activity.
Mangifera indica stem bark and leaves were reported to produce hypoglycemic effects in diabetic rats [11] . However, the comparison of anti-diabetic and hypolipidemic effects of mangiferin in type 1 and type 2 diabetic rats model have not been established. In the present study, we reported comparative evaluations of anti-diabetic and hypolipidemic potentials of mangiferin in streptozotocin-induced type 1 and type 2 diabetic rats model. In addition, in vitro alpha amylase and alpha glucosidase inhibitory effects of mangiferin was investigated.
Materials and Methods

Chemicals and reagents
Standard mangiferin, streptozotocin, starch azure, porcine pancreatic amylase, alpha glucosidase from yeast Saccharomyces cerevisiae, para-nitrophenyl gluco-pyanoside, Tris-HCl buffer and melting point capillary tubes were procured from Sigma Chemicals, USA. Dimethyl sulfoxide, acetic acid, calcium chloride, petroleum ether, acetone, ethanol, methanol, potassium bromide, potassium dihydrogen phosphate, dipotassium hydrogen phosphate and sodium carbonate were purchased from Merck, India. The thin layer chromatography plates were obtained from Merck (silica gel 60 F254 grade, Germany). DMSO-d 6 was obtained from Cambridge Isotope Laboratories Inc, USA. Diagnostic kits and reagents for fasting blood sugar, total cholesterol, triglyceride, high density lipoprotein, low density lipoprotein and very low density lipoprotein were obtained from Merck, India. Acarbose was gifted by Zota Pharmaceutical Pvt. Ltd., Chennai. Insulin (Huminsulin (40 IU/ml), sun pharma, India) and glibenclamide (Aventis Pharma-Mumbai) was procured from local medical market. . Mangifera indica stem barks after collection were dried at room temperature. After complete drying, the dried materials were then grounded to fine powder using a domestic electric grinder (Bajaj appliances, Mumbai).
The dried powdered stem barks of Mangifera indica thus collected (1.3kg) was successively extracted with boiling petroleum ether (2 x 2 L; 6hr each time) to remove fatty matter, with cold acetone (4 x 2 L; 24 hr each time) to remove tannins and finally with 70% ethanolic solvent (4 x 1 L ; 6 hr each time). ). The ethanolic fraction was concentrated under reduced pressure using rotary evaporator (Buchi Rotavapor R-210). Then mangiferin was separated as a yellow colour powder (2.4 gm). Confirmative tests for isolated mangiferin were performed by dissolving isolated mangiferin in aqueous ethanol showed deep yellow colour solution due to presence of mangiferin. In addition, alcoholic solution of isolated mangiferin was treated with ferric chloride and gave deep green colour while with ferric chloride and hydrochloric acid it produced greenish yellow precipitate immediately due to presence of mangiferin [12] .
General experiments
HPTLC analysis was performed using silica gel 60F 254 plates. Known amounts of isolated and standard mangiferin solutions were applied to the layers as band 6mm wide, 10mm from the bottom of the plate using Camag Linomat 5 automated TLC applicator with nitrogen flow. Delivery from syringe was 10µl/sample. Plates were developed at room temperature with ethyl acetate-methanol-water-formic acid (10:1:1:0.5) as solvent system in a Camag twin-trough glass chamber previously saturated with mobile phase vapor for 15 min. After developing the plate, it was dried at 105ºC for 15 min. Peak areas for the isolated and standard mangiferin were recorded at 270 nm using Camag Model-3 TLC Scanner (CAMAG, Switzerland) WinCATS 4 software. Small amount of mangiferin was taken in a melting point capillary tube (sigma) and placed in the melting point apparatus (SUNBIM) and then it was switched on. Then the temperature was gradually increased. At certain temperature range (271ºC-274ºC) the mangiferin was melted and this temperature was notes as melting point of mangiferin. 
Animals
Adult male Wistar Rats (weighing 150-200 g) were used for the investigation. Before the starting of the experiment, the animals were acclimatized to the laboratory conditions for a period of 2 weeks. They were maintained at an ambient temperature (25±2 ºC) and relative humidity (40-60%), with 12/12 h of light/dark cycle. The animals were maintained on balance diet and water ad libitum. Institute Animal Ethical Committee (IAEC) approved the study and all the experiments were carried out by following the guidelines of CPCSEA, India.
Induction of Type 1 Diabetes
Streptozotocin was dissolved in a citrate buffer (pH 4.5). Diabetes was induced by a single intra-peritoneal injection of 75 mg/kg of streptozotocin. After 3 days, blood was collected in vials from the tail vein of overnight fasting rats as selected under guidance of a vet using the aseptic conditions and disposable kits. FBS level of blood was checked regularly up to the stable hyperglycemia stage, usually one week after streptozotocin injection. Rats with blood glucose levels above 250 mg/dl were declared diabetic [13] .
Induction of type 2 diabetes
Type 2 diabetes was induced in overnight fasted rats by a single intraperitoneal injection (i.p.) of streptozotocin (65 mg/kg) in citrate buffer (pH 4.5), 15 min later the administration of nicotinamide (110 mg/kg, i.p.). The animals exhibited fasting glucose levels 140-200 mg/dl after 7 days were screened as type 2 diabetic rats and used for the experiment [14] .
Experimental Design for Type 1 Diabetes
The experiment was carried on five groups (I, II, III, IV and V) of six rats each. Group-I served as normal control Group-II served as diabetic control Group III received 10 mg/kg (i.p) of mangiferin Group IV received 20 mg/kg (i.p) of mangiferin Group V received 40 IU/ml Insulin (Positive control)
Experimental Design for Type 2 Diabetes
The experiment was carried on five groups (I, II, III, IV and V) of six rats each. Group-I served as normal control Group-II served as diabetic control Group III received 10 mg/kg (i.p) of mangiferin Group IV received 20 mg/kg (i.p) of mangiferin Group V received 10mg/kg (i.p) of glibenclamide (Positive control) Intra-peritoneal administration of mangiferin was carried out in diabetic rats daily for 30 days. The blood samples were collected from each rat by retro-orbital venepucture. Biochemical parameters were estimated in both type 1 and type 2 diabetic rats at the beginning and end of the (after 30 days) experiment.
Biochemical parameters
Biochemical parameters notably fasting blood sugar (FBS), total cholesterol (TC), triglycerides (TG), lowdensity lipoprotein (LDL), very low-density lipoprotein (VLDL) levels and high-density lipoprotein (HDL) level in blood serum were measured spectrophotometrically (Semi-Autoanalyzer, Microlab 300, Merck) by using diagnostic kits and reagents obtained from Merck, India.
In vitro alpha amylase inhibitory assay
The assay was carried out following the standard protocol with slight modifications [15] . Starch azure (2 mg) was suspended in a tube containing 0.2ml of 0.5 M Tris-Hcl buffer (pH 6.9) containing 0.01 M calcium chloride (substrate). The tube was boiled for 5 min and then pre-incubated at 37º C for 5 min. Mangiferin (1mg) was dissolved with 1ml of 0.1% of dimethyl sulfoxide in order to obtain concentrations of 10, 20, 40, 60, 80 and 100 µg/ml. Then 0.2 ml of mangiferin of a particular concentration was put in the tube containing the substrate solution. 0.1 ml of porcine pancreatic amylase in Tris-Hcl buffer (2units/ml) was added to the tube containing the mangiferin and substrate solution. The process was carried out at 37º C for 10 min. The reaction was stopped by adding 0.5 ml of 50% acetic acid in each tube. The reaction mixture was then centrifuged (Eppendorf -5804 R) at 3000 rpm for 5 min at 4º C. The absorbance of resulting supernatant was measured at 595nm using spectrophotometer (Perkin Elmer Lambda 25 UV-VIS). The assay was performed in triplicate. The concentration of the mangiferin compound required to inhibit 50% of alpha amylase activity under the conditions was defined as the IC 50 value. The α-amylase inhibitory activity was calculated as follows:
The α-amylase inhibitory activity = (Ac+) -(Ac-) -(AsAb) / (Ac+) -(Ac-) × 100
Where, Ac+, Ac-, As, Ab are defined as the absorbance of 100% enzyme activity (only solvent with enzyme), 0% enzyme activity (only solvent without enzyme), a test sample (with enzyme) and a blank (a test sample without enzyme) respectively.
In vitro alpha glucosidase inhibitory assay
The in vitro alpha glucosidase inhibitory assay was performed with standard protocol [16] . Alpha glucosidase (2U/ml) was premixed with 20 µl of mangiferin at various concentrations (10, 20, 40, 60, 80 and 100 µg/ml) and incubated for 5 min at 37ºC. 1mM para-nitrophenyl gluco-pyanoside (pNPG) (20 µl) in 50mM of phosphate buffer (pH 6.8) was added to initiate the reaction. The mixture was further incubated at 37ºC for 20 min. the reaction was terminated by addition of 50µl of 1M sodium carbonate and the final volume was made up to 150µl. Alpha glucosidase activity was determined spectrophotometrically at 405nm on a Biorad Microplate reader by measuring the quantity of para nitrophenol released from pNPG. The assay was performed in triplicate. The concentration of the mangiferin compound required to inhibit 50% of alpha glucosidase activity under the conditions was defined as the IC 50 value.
Statistical analysis
All values were expressed mean ± standard deviation. All the data were analyzed by one way analysis of variance followed by multiple comparison test (Tukey's test) at the 5% level of significance. P < 0.05 was considered statistically significant. In vitro inhibitory assay statistical difference and linear regression analysis were performed using Graphpad prism 5 statistical software.
Results
Mangiferin (Figure 1 ) a natural glucosyl xanthone was isolated from ethanolic extract of Mangifera indica stem bark (MISB). The HPTLC analysis showed that retention factor (R f ) of standard and isolated mangiferin compound were found to be ≈ 0. + Sterptozotocin (at a dose 75mg/kg, i.p) induced type 1 diabetic rats with fating blood sugar level ranging 250 to 320mg/dl. In type 2 diabetic rats, fasting blood sugar level was slightly higher (170-200 mg/dl) indicating the presence of beta cell functions. Streptozotocin treatment resulted in elevation of fasting blood glucose, triglycerides, total cholesterol, low density lipoprotein and very low density lipoprotein and reduction in high density-lipoprotein levels as compared to the normal control rats. In type 1 diabetic model, the body weight was slightly increased in normal control rats compared to initial body weight whereas streptozotocin-induced diabetic rats showed loss of body weight (192±1.72g) after 30 days as compared with initially weight of diabetic rats (201.8±2.69g). Body weight of diabetic rats was restored significantly (P<0.05) by treating with insulin (40 IU/ml) and glibenclamide (10mg/kg) in type 1 and type 2diabetic model respectively. In type 1 diabetic model, body weight of diabetic rats was not restored by treating with mangiferin (at a dose 10 and 20 mg/kg, i.p) daily for 30 days when compared with diabetic control (Table 1) . But in case of type 2 diabetic model, body weight of diabetic rats was significantly (P<0.05) restored by treating with mangiferin (at a dose 10 and 20 mg/kg, i.p) daily for 30 days when compared with diabetic control (Table  2 ). In type 1 diabetic model, mangiferin (at a dose 10 and 20 mg/kg, i.p) showed no anti-diabetic and hypolipidemic effects when compared with diabetic control rats (Table 3) . But the insulin (40 IU/ml) showed anti-diabetic and hypolipidemic effects in type 1 diabetic model rats when compared with diabetic control rats. In type 2 diabetic models, mangiferin (at a dose 10 and 20 mg/kg, i.p) exhibited potential antidiabetic and hypolipidemic effects when compared with diabetic control rats (Table 4) . Further, glibenclamide also showed significant anti-diabetic and hypolipidemic effects in type 2 diabetic models. In type 2 diabetic model, mangiferin (at a dose 10 and 20 mg/kg, i.p) exhibited significant (P<0.05) reduction of fasting blood sugar level (195 (Figure 4) , it was observed that mangiferin exhibited appreciable alpha amylase inhibitory effects (IC 50 value 74.35±1.9µg/ml) and alpha glucosidase inhibitory effects (IC 50 41.88±3.9µg/ml) when compared with acarbose (IC 50 83.33±1.2µg/ml).
Discussion
The present study was undertaken to investigate the anti-diabetic and hypolipidemic effects of mangiferin in type 1 and type 2 diabetic rats model. When compared with the FTIR spectra, Electron-Spray Ionization (ESI) -Mass spectrum, 1 H and 13 C NMR spectrum of standard mangiferin, the sample (isolated mangiferin) showed significant similarity. Insulin was used as a standard drug for type 1 diabetic model rats and glibenclamide for type 2 diabetic rats model. It is well established that insulin activate glucose uptake in various cells including adipocytes and muscles. On the other hand, glibenclamide (a long lasting sulfonylurea) acts on mainly by stimulating insulin secretion. In the present study indicated that daily administration of mangiferin (at a dose 10 and 20 mg/kg, i.p) up to 30 days showed anti-diabetic and hypolipidemic effects in type 2 diabetic rats. This is an interesting, as the continuous use of mangiferin in the type 1 and type 2 diabetic rats will not result in hypoglycemic shock. In type 1 diabetic model rats, an increase in blood sugar levels in diabetic rats was observed after the induction of diabetes by streptozotocin. Mangiferin (at a dose 10 and 20 mg/kg, i.p) showed no anti-diabetic and hypolipidemic effects in type 1 diabetic model when compared with insulin.
In type 2 diabetic model rats, an increase in blood sugar levels in diabetic rats were prevented by mangiferin (at a dose 10 and 20 mg/kg, i.p). The effects were comparable to the standard drug glibenclamide. This effect may be due either to potentiating of the effect of insulin which had been secreted from the remaining beta cells or its release from the bound form. Since, lipid abnormalities accompanying with atherosclerosis is the major cause of cardiovascular disease in diabetes. Therefore ideal treatment of diabetes, in addition to glycemic control, should have a favorable effect on lipid profiles. High level of TC and LDL are major coronary risk factors [17] . Further, the studies suggested that TG itself is indendently related to coronary heart disease [18, 19] . The abnormalities in lipid metabolism lead to elevation in the levels of serum lipid and lipoprotein that in turn play an important role in occurrence of premature and severe atherosclerosis, which affects patients with diabetes [20] . Hence, measurements of biochemical parameters are necessary to prevent cardiac complications in diabetes condition. In this study, mangiferin (at a dose 10 and 20 mg/kg) showed significant reduction in TC, TG, LDL, VLDL levels and increased level of HDL in type 2 diabetic model rats. However, HDL (cardioprotective lipid) level was increased by mangiferin when compared with glibenclamide. Therefore, mangiferin has potential role to prevent formation of atherosclerosis and coronary heart disease in type 2 diabetes. In type 1 diabetic model, body weight of diabetic rats was not restored by treating with mangiferin (at a dose 10 and 20 mg/kg, i.p) daily for 30 days but the diabetic rats body weight was restored by treating with insulin (40IU/ml) in type 1 diabetic model. In case of type 2 diabetic model, body weight of diabetic rats was significantly restored by treating with mangiferin (at a dose 10 and 20 mg/kg, i.p) daily for 30 days when compared with standard glibenclamide (10mg/kg). The weight loss in diabetic rats may be associated with lipid lowering activity of mangiferin or due to its influence on various lipid regulation systems. Several studies reported that Mangifera indica and its polyphenol compound mangiferin possess anti-diabetic activity. Oral administration of aqueous extract (1g/kg) of Mangifera indica showed hypoglycemic activity in diabetic mice [21] . Stem bark extract of Mangifera indica showed potent antioxidant effects both in vitro and in vivo [22] . Components of stem bark extract of Mangifera indica such as terpenoids, cathechin, fatty acids and microelements exhibited antioxidant properties [23, 24] . Aqueous extract from the bark of Mangifera indica was used as a food supplement in Cuba showed potent in vitro and in vivo antioxidant activities [25] . Mangiferin showed anti-diabetic activity in KK-Ay mice and it could be useful for treatment of Type 2 diabetes [26] . Mangiferin was found to reduce plasma total cholesterol, triglycerides and LDL associated with concomitant increase in HDL levels and decreased atherogenic index in diabetic rats indicating its potent anti-hyperglycemic and antiatherogenic property. The accumulating evidences suggest that both pancreatic and extra pancreatic mechanisms might be involved in its anti-diabetic or anti-hyperglycemic action [27] . According to the Randle's glucose-fatty acid cycle, increased supply of plasma triglycerides could constitute a source of increased free fatty acid availability and oxidation that can impair insulin action, glucose metabolism and utilization leading to development of hyperglycemia. Therefore the reduction of triglycerides following administration with mangiferin would also facilitate the glucose oxidation and utilization and subsequently the reduction of hyperglycemia [28] . In the present study clearly indicated that mangiferin exhibited antidiabetic as well as hypolipidemic effects by lowering FBS, TC, TG, LDL, and VLDL levels coupled together with elevation of HDL level in type 2 diabetic model rats. In addition, one of the therapeutic approaches for type 2 diabetes is to reduce the postprandial hyperglycemia. Alpha amylase and alpha glucosidase are the enzymes involved in the metabolism of carbohydrates. Alpha amylase degrades complex dietary carbohydrates to oligosaccharides and disaccharides, which are ultimately converted into monosaccharide by alpha glucosidase. Liberated glucose is then absorbed by the gut and results in postprandial hyperglycemia. Inhibition of alpha amylase and alpha glucosidase limits postprandial glucose levels by delaying the process of carbohydrate hydrolysis and absorption [29] . The plant based alpha amylase and alpha glucosidase inhibitor offers a prospective therapeutic approach for the management of post-prandial hyperglycemia [30] . In the present study, mangiferin exhibited appreciable alpha amylase and alpha glucosidase inhibitory effects when compared with standard drug acarbose. Therefore, mangiferin could be useful in management of postprandial hyperglycemia due to inhibition of both alpha amylase and alpha glucosidase enzymes.
Conclusion
The present study demonstrated that mangiferin could be useful in management of type 2 diabetes associated with abnormalities in lipid profiles. The study needs to be validated in human volunteers to claim for its further usage in human volunteers.
